{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:00:19Z","timestamp":1791234019739,"version":"4.1.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00105-024-05359-y","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T07:04:09Z","timestamp":1718348649000},"page":"655-673","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Topische und systemische antimykotische Behandlung von Dermatomykosen","Dermatomycoses: topical and systemic antifungal treatment"],"prefix":"10.1007","volume":"75","author":[{"given":"Pietro","family":"Nenoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Klonowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Uhrla\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schaller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Paasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mayser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,14]]},"reference":[{"issue":"9","key":"5359_CR1","first-page":"718","volume":"67","author":"A D\u00fcrrbeck","year":"2016","unstructured":"D\u00fcrrbeck\u00a0A, Nenoff\u00a0P (2016) Terbinafin: Relevante Arzneimittelinteraktionen und deren Management. Dermatologie 67(9):718\u2013723","journal-title":"Dermatologie"},{"issue":"9","key":"5359_CR2","first-page":"724","volume":"67","author":"P Mayser","year":"2016","unstructured":"Mayser\u00a0P (2016) Terbinafin: Medikamenteninduzierter Lupus erythematodes und Triggerung psoriatischer Hautver\u00e4nderungen. Dermatologie 67(9):724\u2013731","journal-title":"Dermatologie"},{"issue":"2","key":"5359_CR3","first-page":"161","volume":"18","author":"P Mayser","year":"2020","unstructured":"Mayser\u00a0P, Nenoff\u00a0P, Reinel\u00a0D et\u00a0al (2020) S1-Leitlinie: Tinea capitis. J\u00a0Dtsch Dermatol Ges 18(2):161\u2013180","journal-title":"J Dtsch Dermatol Ges"},{"key":"5359_CR4","first-page":"17","volume-title":"Trichophyton indotineae oder Trichophyton mentagrophytes Genotyp\u00a0VIII \u2013 ein neuer Terbinafin-resistenter Dermatophyt aus Indien in Deutschland und \u00d6sterreich","author":"P Nenoff","year":"2022","unstructured":"Nenoff\u00a0P, Uhrla\u00df\u00a0S (2022) Trichophyton indotineae oder Trichophyton mentagrophytes Genotyp\u00a0VIII \u2013 ein neuer Terbinafin-resistenter Dermatophyt aus Indien in Deutschland und \u00d6sterreich, S\u00a017\u201320 (Spectrum Dermatologie FOCUS \u201eDermatomykologie\u201c)"},{"issue":"6","key":"5359_CR5","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s11046-020-00455-8","volume":"185","author":"R Kano","year":"2020","unstructured":"Kano\u00a0R, Kimura\u00a0U, Kakurai\u00a0M et\u00a0al (2020) Trichophyton indotineae sp. nov.: a\u00a0new highly terbinafine-resistant anthropophilic dermatophyte species. Mycopathologia 185(6):947\u2013958","journal-title":"Mycopathologia"},{"issue":"10","key":"5359_CR6","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1007\/s00105-021-04879-1","volume":"72","author":"L Appelt","year":"2021","unstructured":"Appelt\u00a0L, Nenoff\u00a0P, Uhrla\u00df\u00a0S et\u00a0al (2021) Terbinafin-resistente Dermatophytosen und Onychomykose durch Trichophyton rubrum. Hautarzt 72(10):868\u2013877","journal-title":"Hautarzt"},{"issue":"11","key":"5359_CR7","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1007\/s00105-023-05232-4","volume":"74","author":"P Nenoff","year":"2023","unstructured":"Nenoff\u00a0P, Stahl\u00a0M, Schaller\u00a0M et\u00a0al (2023) Rezidivierende Tinea corporis generalisata durch einen Terbinafin-resistenten Trichophyton-rubrum-Stamm : Langzeitbehandlung mit Super-Bioavailability-Itraconazol. Dermatologie 74(11):864\u2013873","journal-title":"Dermatologie"},{"key":"5359_CR8","doi-asserted-by":"publisher","DOI":"10.7547\/21-240","author":"AK Gupta","year":"2023","unstructured":"Gupta\u00a0AK, Hall\u00a0DC, Simkovich\u00a0AJ (2023) How effective are devices in the management of onychomycosis?: A\u00a0systematic review. J\u00a0Am Podiatr Med Assoc. https:\/\/doi.org\/10.7547\/21-240","journal-title":"J Am Podiatr Med Assoc"},{"issue":"9","key":"5359_CR9","first-page":"1248","volume":"20","author":"U Paasch","year":"2022","unstructured":"Paasch\u00a0U, Zidane\u00a0M, Baron\u00a0JM et\u00a0al (2022) S2k-Leitlinie: Lasertherapie der Haut. J\u00a0Dtsch Dermatol Ges 20(9):1248\u20131270","journal-title":"J Dtsch Dermatol Ges"},{"key":"5359_CR10","unstructured":"US Food and Drug Administration (2016) Medical devices and clinical trial design for the treatment or improvement in the appearance of fungally-infected nails. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/medical-devices-and-clinical-trial-design-treatment-or-improvement-appearance-fungally-infected. Zugegriffen: 1. Sept. 2023"},{"issue":"6","key":"5359_CR11","first-page":"678","volume":"21","author":"P Nenoff","year":"2023","unstructured":"Nenoff\u00a0P, Reinel\u00a0D, Mayser\u00a0P et\u00a0al (2023) S1-Leitlinie Onychomykose. J\u00a0Dtsch Dermatol Ges 21(6):678\u2013694","journal-title":"J Dtsch Dermatol Ges"},{"key":"5359_CR12","unstructured":"Mayser P (2022) Mykologische Fortbildung \u2013 Teil\u00a012: Systemische antimykotische Therapie. Wann und wie? https:\/\/dermatologie.almirallmed.de\/publikationen\/mykologische-fortbildung-eine-fortbildungsreihe"},{"key":"5359_CR13","unstructured":"Hof H, Schl\u00fcter D (Hrsg) Medizinische Mikrobiologie, 8.\u00a0Aufl. Thieme, Stuttgart"},{"key":"5359_CR14","volume-title":"Antimykotika von A\u2013Z, Therapie der Mykosen von der Ambulanz bis zur Intensivmedizin","author":"H-J Tietz","year":"2011","unstructured":"Tietz\u00a0H\u2011J (2011) Antimykotika von A\u2013Z, Therapie der Mykosen von der Ambulanz bis zur Intensivmedizin, 5.\u00a0Aufl. Ligatur Verlag, Stuttgart","edition":"5"},{"key":"5359_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9080445","author":"G Wall","year":"2020","unstructured":"Wall\u00a0G, Lopez-Ribot\u00a0JL (2020) Current antimycotics, new prospects, and future approaches to antifungal therapy. Antibiotics. https:\/\/doi.org\/10.3390\/antibiotics9080445","journal-title":"Antibiotics"},{"key":"5359_CR16","volume-title":"Antibiotika und Antimykotika","author":"G Ackermann","year":"2013","unstructured":"Ackermann\u00a0G (2013) Antibiotika und Antimykotika, 4.\u00a0Aufl. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart","edition":"4"},{"issue":"5","key":"5359_CR17","first-page":"387","volume":"13","author":"P Nenoff","year":"2015","unstructured":"Nenoff\u00a0P, Kr\u00fcger\u00a0C, Paasch\u00a0U et\u00a0al (2015) Mykologie \u2013 ein Update. Teil\u00a03: Dermatomykosen: topische und systemische Behandlung. J\u00a0Dtsch Dermatol Ges 13(5):387\u2013410 (quiz 411)","journal-title":"J Dtsch Dermatol Ges"},{"key":"5359_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19253","author":"G Blanchard","year":"2023","unstructured":"Blanchard\u00a0G, Amarov\u00a0B, Fratti\u00a0M et\u00a0al (2023) Reliable and rapid identification of terbinafine resistance in dermatophytic nail and skin infections. J\u00a0Eur Acad Dermatol Venereol. https:\/\/doi.org\/10.1111\/jdv.19253","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"5359_CR19","doi-asserted-by":"publisher","first-page":"468","DOI":"10.25259\/IJDVL_303_20","volume":"87","author":"SB Verma","year":"2021","unstructured":"Verma\u00a0SB, Panda\u00a0S, Nenoff\u00a0P et\u00a0al (2021) The unprecedented epidemic-like scenario of dermatophytosis in India: III. Antifungal resistance and treatment options. Indian J Dermatol Venereol Leprol 87(4):468\u2013482","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"10","key":"5359_CR20","first-page":"900","volume":"72","author":"A Gawaz","year":"2021","unstructured":"Gawaz\u00a0A, Nenoff\u00a0P, Uhrla\u00df\u00a0S et\u00a0al (2021) Therapie eines Terbinafin-resistenten Trichophyton mentagrophytes Typ\u00a0VIII. Dermatologie 72(10):900\u2013904","journal-title":"Dermatologie"},{"issue":"3","key":"5359_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s11046-021-00544-2","volume":"186","author":"C Tang","year":"2021","unstructured":"Tang\u00a0C, Kong\u00a0X, Ahmed\u00a0SA et\u00a0al (2021) Taxonomy of the Trichophyton mentagrophytes\/T.\u00a0interdigitale species complex harboring the highly virulent, multiresistant genotype T.\u00a0indotineae. Mycopathologia 186(3):315\u2013326","journal-title":"Mycopathologia"},{"issue":"6","key":"5359_CR22","doi-asserted-by":"publisher","first-page":"800","DOI":"10.25259\/IJDVL_1025_19","volume":"87","author":"S Tahiliani","year":"2021","unstructured":"Tahiliani\u00a0S, Saraswat\u00a0A, Lahiri\u00a0AK et\u00a0al (2021) Etiological prevalence and antifungal sensitivity patterns of dermatophytosis in India\u2014a multicentric study. Indian J Dermatol Venereol Leprol 87(6):800\u2013806","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"7","key":"5359_CR23","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1111\/ijd.16362","volume":"62","author":"AK Gupta","year":"2023","unstructured":"Gupta\u00a0AK, Venkataraman\u00a0M, Hall\u00a0DC et\u00a0al (2023) The emergence of Trichophyton indotineae: implications for clinical practice. Int J Dermatol 62(7):857\u2013861","journal-title":"Int J Dermatol"},{"issue":"20","key":"5359_CR24","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1056\/NEJMicm1311831","volume":"370","author":"P Nenoff","year":"2014","unstructured":"Nenoff\u00a0P, Schetschorke\u00a0C (2014) Images in clinical medicine. Tinea faciei. N\u00a0Engl J Med 370(20):e31","journal-title":"N Engl J Med"},{"issue":"8","key":"5359_CR25","first-page":"601","volume":"70","author":"H Kirsten","year":"2019","unstructured":"Kirsten\u00a0H, Haiduk\u00a0J, Nenoff\u00a0P et\u00a0al (2019) Tinea barbae profunda durch Trichophyton mentagrophytes \u2013 Patientenbeschreibung und \u00dcbersicht. Dermatologie 70(8):601\u2013611","journal-title":"Dermatologie"},{"issue":"2","key":"5359_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1439-0507.2007.01426.x","volume":"50","author":"P Nenoff","year":"2007","unstructured":"Nenoff\u00a0P, M\u00fcgge\u00a0C, Herrmann\u00a0J et\u00a0al (2007) Tinea faciei incognito due to Trichophyton rubrum as a\u00a0result of autoinoculation from onychomycosis. Mycoses 50(2):20\u201325","journal-title":"Mycoses"},{"issue":"2","key":"5359_CR27","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3897\/folmed.63.e54559","volume":"63","author":"G Vazheva","year":"2021","unstructured":"Vazheva\u00a0G, Zisova\u00a0L (2021) Tinea barbae profunda caused by Trichophyton rubrum\u2014an autoinoculation from a\u00a0primary tinea pedis. Folia Med 63(2):292\u2013296","journal-title":"Folia Med"},{"issue":"4","key":"5359_CR28","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/myc.13231","volume":"64","author":"VL M\u00fcller","year":"2021","unstructured":"M\u00fcller\u00a0VL, Kappa-Markovi\u00a0K, Hyun\u00a0J et\u00a0al (2021) Tinea capitis et barbae caused by Trichophyton tonsurans: a\u00a0retrospective cohort study of an infection chain after shavings in barber shops. Mycoses 64(4):428\u2013436","journal-title":"Mycoses"},{"issue":"8","key":"5359_CR29","first-page":"648","volume":"63","author":"R-H Bl\u00f6mer","year":"2012","unstructured":"Bl\u00f6mer\u00a0R\u2011H, Keilani\u00a0N, Faber\u00a0A et\u00a0al (2012) Tinea capitis profunda durch Trichophyton verrucosum mit abszedierender Superinfektion durch cMRSA bei einem Kleinkind. Dermatologie 63(8):648\u2013652","journal-title":"Dermatologie"},{"key":"5359_CR30","first-page":"12","volume":"24","author":"P Nenoff","year":"2018","unstructured":"Nenoff\u00a0P, Uhrla\u00df\u00a0S, Bethge\u00a0A et\u00a0al (2018) Tinea capitis profunda durch Trichophyton quinckeanum. Derm Prakt Dermatol 24:12\u201323","journal-title":"Derm Prakt Dermatol"},{"issue":"2","key":"5359_CR31","first-page":"136","volume":"69","author":"P Nenoff","year":"2018","unstructured":"Nenoff\u00a0P, Schulze\u00a0I, Kr\u00fcger\u00a0C et\u00a0al (2018) 7\/m mit eitrig abszedierender, druckschmerzhafter L\u00e4sion am Kapillitium: Vorbereitung auf die Facharztpr\u00fcfung: Folge 14. Dermatologie 69(2):136\u2013144","journal-title":"Dermatologie"},{"issue":"3","key":"5359_CR32","first-page":"250","volume":"27","author":"P Nenoff","year":"2021","unstructured":"Nenoff\u00a0P, Kunz\u00a0M, Wei\u00dfer\u00a0M et\u00a0al (2021) Eitrig abszedierende Kopfhautinfektion bei einem 2j\u00e4hrigen Kind. Diagnosequiz. Derm Prakt Dermatol 27(3):250\u2013260","journal-title":"Derm Prakt Dermatol"},{"issue":"2","key":"5359_CR33","first-page":"161","volume":"18","author":"P Mayser","year":"2020","unstructured":"Mayser\u00a0P, Nenoff\u00a0P, Reinel\u00a0D et\u00a0al (2020) S1 guidelines: Tinea capitis. J\u00a0Dtsch Dermatol Ges 18(2):161\u2013179","journal-title":"J Dtsch Dermatol Ges"},{"issue":"5","key":"5359_CR34","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s13555-020-00420-9","volume":"10","author":"BM Piraccini","year":"2020","unstructured":"Piraccini\u00a0BM, Iorizzo\u00a0M, Lencastre\u00a0A et\u00a0al (2020) Ciclopirox Hydroxypropyl Chitosan (HPCH) nail lacquer: a\u00a0review of its use in onychomycosis. Dermatol Ther (Heidelb) 10(5):917\u2013929","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"5359_CR35","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1159\/000443773","volume":"1","author":"JM Evans","year":"2016","unstructured":"Evans\u00a0JM, Wang\u00a0AL, Elewski\u00a0BE (2016) Successful treatment of Paecilomyces lilacinus onychomycosis with efinaconazole and tavaborole. Skin Appendage Disord 1(4):169\u2013171","journal-title":"Skin Appendage Disord"},{"key":"5359_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27206850","author":"SA Salami","year":"2022","unstructured":"Salami\u00a0SA, Siwe-Noundou\u00a0X, Krause\u00a0RWM (2022) A more sustainable Isocyanide synthesis from N\u2011substituted formamides using phosphorus oxychloride in the presence of triethylamine as solvent. Molecules. https:\/\/doi.org\/10.3390\/molecules27206850","journal-title":"Molecules"},{"issue":"1","key":"5359_CR37","doi-asserted-by":"publisher","first-page":"e13683","DOI":"10.1111\/myc.13683","volume":"67","author":"AK Gupta","year":"2024","unstructured":"Gupta\u00a0AK, Elewski\u00a0B, Joseph\u00a0WS et\u00a0al (2024) Treatment of onychomycosis in an era of antifungal resistance: role for antifungal stewardship and topical antifungal agents. Mycoses 67(1):e13683","journal-title":"Mycoses"},{"issue":"29","key":"5359_CR38","first-page":"509","volume":"113","author":"U Wollina","year":"2016","unstructured":"Wollina\u00a0U, Nenoff\u00a0P, Haroske\u00a0G et\u00a0al (2016) Diagnostik und Therapie von Nagelerkrankungen. Dtsch \u00c4rztebl Int 113(29):509\u2013518","journal-title":"Dtsch \u00c4rztebl Int"},{"issue":"1","key":"5359_CR39","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s15011-018-1759-8","volume":"66","author":"H-J Tietz","year":"2018","unstructured":"Tietz\u00a0H\u2011J, Gunkel\u00a0U (2018) Onychomykose: Chancen auf Heilung sind besser denn je. Dtsch Dermatolog 66(1):36\u201341","journal-title":"Dtsch Dermatolog"},{"key":"5359_CR40","unstructured":"Aktuelle Fachinformation Terbinafin Al Tbl. 250\u202fmg. https:\/\/www.fachinfo.de\/suche\/fi\/008884. Zugegriffen: 25. Sept. 2023"},{"key":"5359_CR41","first-page":"42","volume":"39","author":"H-J Tietz","year":"2017","unstructured":"Tietz\u00a0H\u2011J (2017) Onychomykose bei Erwachsenen und Kindern. Erfolgreiche Therapie in der t\u00e4glichen Praxis. Allgemeinarzt 39:42\u201347","journal-title":"Allgemeinarzt"},{"issue":"07","key":"5359_CR42","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1055\/a-1150-0809","volume":"46","author":"I Effendy","year":"2020","unstructured":"Effendy\u00a0I, Mayer\u00a0J, Nenoff\u00a0P et\u00a0al (2020) Kombinationstherapie von schweren Onychomykosen \u2013 Empfehlungen eines Expertengremiums. Akt Dermatol 46(07):311\u2013318","journal-title":"Akt Dermatol"},{"key":"5359_CR43","first-page":"236","volume":"27","author":"H-J Tietz","year":"2021","unstructured":"Tietz\u00a0H\u2011J, Gunkel\u00a0U (2021) Pilzinfektionen in Zeiten von COVID-19: Schwerpunktthema Mykosen bei Kindern. Derm Prakt Dermatol 27:236\u2013242","journal-title":"Derm Prakt Dermatol"},{"issue":"6","key":"5359_CR44","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/myc.13248","volume":"64","author":"A Farr","year":"2021","unstructured":"Farr\u00a0A, Effendy\u00a0I, Frey Tirri\u00a0B et\u00a0al (2021) Guideline: vulvovaginal candidosis (AWMF 015\/072, level S2k). Mycoses 64(6):583\u2013602","journal-title":"Mycoses"},{"issue":"7","key":"5359_CR45","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1111\/jdv.18982","volume":"37","author":"MAS Henning","year":"2023","unstructured":"Henning\u00a0MAS, Hay\u00a0R, Rodriguez-Cerdeira\u00a0C et\u00a0al (2023) Position statement: recommendations on the diagnosis and treatment of Malassezia folliculitis. J\u00a0Eur Acad Dermatol Venereol 37(7):1268\u20131275","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"5359_CR46","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1439-0507.2009.01820.x","volume":"53","author":"PO Gubbins","year":"2010","unstructured":"Gubbins\u00a0PO, Heldenbrand\u00a0S (2010) Clinically relevant drug interactions of current antifungal agents. Mycoses 53(2):95\u2013113","journal-title":"Mycoses"},{"key":"5359_CR47","unstructured":"Fachinformation Crestor\u00ae 5\u202fmg\/10\u202fmg\/20\u202fmg Filmtabletten\/Rosuvastatin"},{"key":"5359_CR48","doi-asserted-by":"publisher","DOI":"10.3238\/persinfek.2017.04.28.08","author":"H Petri","year":"2017","unstructured":"Petri\u00a0H (2017) Arzneimitteltherapiesicherheit: Interaktionspotenzial der Azol-Antimykotika. Dtsch Arztebl Online. https:\/\/doi.org\/10.3238\/persinfek.2017.04.28.08","journal-title":"Dtsch Arztebl Online"},{"issue":"3","key":"5359_CR49","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s40266-021-00917-8","volume":"39","author":"AK Gupta","year":"2022","unstructured":"Gupta\u00a0AK, Venkataraman\u00a0M, Talukder\u00a0M (2022) Onychomycosis in older adults: prevalence, diagnosis, and management. Drugs Aging 39(3):191\u2013198","journal-title":"Drugs Aging"},{"issue":"17","key":"5359_CR50","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3238\/PersInfek.2017.04.28.08","volume":"114","author":"H Petri","year":"2017","unstructured":"Petri H (2017) Arzneimitteltherapiesicherheit: Interaktionspotenzial der Azol-Antimykotika. Dtsch Arztebl 114(17):22\u201324. https:\/\/doi.org\/10.3238\/PersInfek.2017.04.28.08","journal-title":"Dtsch Arztebl"},{"key":"5359_CR51","unstructured":"Aktuelle Fachinformation Diflucan Derm 50\u202fmg Hartkapseln. https:\/\/www.fachinfo.de\/suche\/fi\/007630. Zugegriffen: 25. Sept. 2023"},{"key":"5359_CR52","unstructured":"Drug interactions Flockhart table. https:\/\/drug-interactions.medicine.iu.edu\/MainTable.aspx. Zugegriffen: 26. Juni 2023"},{"key":"5359_CR53","unstructured":"Aktuelle Fachinformation Sempera 100\u202fmg Kapseln. https:\/\/www.fachinfo.de\/suche\/fi\/004004. Zugegriffen: 25. Sept. 2023"},{"issue":"2","key":"5359_CR54","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.jaad.2020.04.172","volume":"84","author":"Y Wang","year":"2021","unstructured":"Wang\u00a0Y, Geizhals\u00a0S, Lipner\u00a0SR (2021) Retrospective analysis of laboratory abnormalities in patients prescribed terbinafine for onychomycosis. J\u00a0Am Acad Dermatol 84(2):497\u2013499","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"5359_CR55","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/bjd.15854","volume":"177","author":"ON Kramer","year":"2017","unstructured":"Kramer\u00a0ON, Albrecht\u00a0J (2017) Clinical presentation of terbinafine-induced severe liver injury and the value of laboratory monitoring: a\u00a0critically appraised topic. Br J Dermatol 177(5):1279\u20131284","journal-title":"Br J Dermatol"},{"key":"5359_CR56","unstructured":"Mayser P, Nenoff P, Reinel D et\u00a0al (2020) S1-Leitlinie: Tinea capitis. https:\/\/www.awmf.org\/leitlinien\/detail\/ll\/013-033 (AWMF-Register-Nr. 013-033)"},{"issue":"8","key":"5359_CR57","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s10103-019-02802-8","volume":"34","author":"K Yeung","year":"2019","unstructured":"Yeung\u00a0K, Ortner\u00a0VK, Martinussen\u00a0T et\u00a0al (2019) Efficacy of laser treatment for onychomycotic nails: a\u00a0systematic review and meta-analysis of prospective clinical trials. Lasers Med Sci 34(8):1513\u20131525","journal-title":"Lasers Med Sci"},{"issue":"1","key":"5359_CR58","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/0007-1226(76)90104-1","volume":"29","author":"I Kaplan","year":"1976","unstructured":"Kaplan\u00a0I, Labandter\u00a0H (1976) Onychogryphosis treated with the CO2 surgical laser. Br J Plast Surg 29(1):102\u2013103","journal-title":"Br J Plast Surg"},{"key":"5359_CR59","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13657","author":"B Ramzy","year":"2023","unstructured":"Ramzy\u00a0B, Emily\u00a0A\u2011H, Jiryis\u00a0B et\u00a0al (2023) Nd:YAG 1064\u202fnm laser treatment for onychomycosis\u2014is it really effective? A\u00a0prospective assessment for efficiency and factors contributing to response. Mycoses. https:\/\/doi.org\/10.1111\/myc.13657","journal-title":"Mycoses"},{"issue":"11","key":"5359_CR60","doi-asserted-by":"publisher","first-page":"386","DOI":"10.52403\/ijrr.20221152","volume":"9","author":"P Mehta","year":"2022","unstructured":"Mehta\u00a0P, Vora\u00a0D, Patel\u00a0N (2022) Study of fractional carbon dioxide laser in treatment of onychomycosis (100 cases). Int J Res Rev 9(11):386\u2013391","journal-title":"Int J Res Rev"},{"issue":"1","key":"5359_CR61","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s10103-023-03804-3","volume":"38","author":"P Shetty","year":"2023","unstructured":"Shetty\u00a0P, Rangegowda\u00a0SM, Vinay\u00a0KN et\u00a0al (2023) Comparative study of safety and efficacy of combination therapy of fractional CO2 laser and topical amorolfine cream versus oral itraconazole in the treatment of onychomycosis. Lasers Med Sci 38(1):147","journal-title":"Lasers Med Sci"},{"issue":"1","key":"5359_CR62","doi-asserted-by":"publisher","first-page":"47","DOI":"10.25259\/IJDVL_98_2021","volume":"89","author":"E Ranjan","year":"2023","unstructured":"Ranjan\u00a0E, Arora\u00a0S, Sharma\u00a0N (2023) Fractional CO2 laser with topical 1\u202f% terbinafine cream versus oral itraconazole in the management of onychomycosis: a\u00a0randomized controlled trial. Indian J Dermatol Venereol Leprol 89(1):47\u201353","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"4","key":"5359_CR63","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1159\/000527252","volume":"9","author":"E Ranjan","year":"2023","unstructured":"Ranjan\u00a0E, Arora\u00a0S, Sharma\u00a0AS et\u00a0al (2023) Single-session fractional CO2 laser following urea occlusion in management of onychomycosis: a\u00a0pilot study. Skin Appendage Disord 9(4):268\u2013274","journal-title":"Skin Appendage Disord"},{"issue":"1","key":"5359_CR64","first-page":"33","volume":"12","author":"P Nenoff","year":"2014","unstructured":"Nenoff\u00a0P, Grunewald\u00a0S, Paasch\u00a0U (2014) Laser therapy of onychomycosis. J\u00a0Dtsch Dermatol Ges 12(1):33\u201338","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"5359_CR65","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s15010-021-01691-w","volume":"49","author":"S Gnat","year":"2021","unstructured":"Gnat\u00a0S, \u0141agowski\u00a0D, Dyl\u0105g\u00a0M et\u00a0al (2021) Cold atmospheric pressure plasma (CAPP) as a\u00a0new alternative treatment method for onychomycosis caused by Trichophyton verrucosum: in vitro studies. Infection 49(6):1233\u20131240","journal-title":"Infection"},{"key":"5359_CR66","doi-asserted-by":"crossref","first-page":"6052461","DOI":"10.1155\/2020\/6052461","volume":"2020","author":"R-N Zhang","year":"2020","unstructured":"Zhang\u00a0R\u2011N, Zhao\u00a0J\u2011Y, Li\u00a0L\u2011F (2020) Morphological and transcriptome analyses provide insights into growth inhibition of Trichophyton rubrum caused by laser irradiation. Evid Based Complement Alternat Med 2020:6052461","journal-title":"Evid Based Complement Alternat Med"},{"key":"5359_CR67","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.34172\/jlms.2023.35","volume":"14","author":"T Razavyoon","year":"2023","unstructured":"Razavyoon\u00a0T, Hashemi\u00a0SJ, Mansouri\u00a0P et\u00a0al (2023) Effect of the 1064\u202fnm Nd: YAG laser on the MICs of antifungals used in clinical practice for the treatment of fungal nail infections. J\u00a0Lasers Med Sci 14:e35","journal-title":"J Lasers Med Sci"},{"issue":"6","key":"5359_CR68","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/lsm.23541","volume":"54","author":"VK Ortner","year":"2022","unstructured":"Ortner\u00a0VK, Nguyen\u00a0N, Brewer\u00a0JR et\u00a0al (2022) Fractional CO2 laser ablation leads to enhanced permeation of a\u00a0fluorescent dye in healthy and mycotic nails\u2014an imaging investigation of laser-tissue effects and their impact on ungual drug delivery. Lasers Surg Med 54(6):861\u2013874","journal-title":"Lasers Surg Med"},{"issue":"48","key":"5359_CR69","doi-asserted-by":"publisher","first-page":"e17948","DOI":"10.1097\/MD.0000000000017948","volume":"98","author":"W Ma","year":"2019","unstructured":"Ma\u00a0W, Si\u00a0C, Kasyanju Carrero\u00a0LM et\u00a0al (2019) Laser treatment for onychomycosis: a\u00a0systematic review and meta-analysis. Medicine 98(48):e17948","journal-title":"Medicine"},{"issue":"9","key":"5359_CR70","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1007\/s10103-020-03086-z","volume":"35","author":"V Madan","year":"2020","unstructured":"Madan\u00a0V (2020) Resumption of laser\/IPL skin services post COVID-19 lockdown-British medical laser association (BMLA) guidance document. Lasers Med Sci 35(9):2069\u20132073","journal-title":"Lasers Med Sci"},{"issue":"2","key":"5359_CR71","first-page":"37","volume":"41","author":"Q Dong","year":"2023","unstructured":"Dong\u00a0Q, Kang\u00a0Y, Zhang\u00a0R (2023) Treatment of superficial mycoses using photodynamic therapy: a\u00a0systematic review and meta-analysis. Photobiomodul Photomed Laser Surg 41(2):37\u201347","journal-title":"Photobiomodul Photomed Laser Surg"},{"key":"5359_CR72","doi-asserted-by":"publisher","DOI":"10.1111\/php.13839","author":"A Bekmukhametova","year":"2023","unstructured":"Bekmukhametova\u00a0A, Antony\u00a0A, Halliday\u00a0C et\u00a0al (2023) Rose bengal-encapsulated chitosan nanoparticles for the photodynamic treatment of Trichophyton species. Photochem Photobiol. https:\/\/doi.org\/10.1111\/php.13839","journal-title":"Photochem Photobiol"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-024-05359-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-024-05359-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-024-05359-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T20:59:05Z","timestamp":1732222745000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-024-05359-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,14]]},"references-count":72,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["5359"],"URL":"https:\/\/doi.org\/10.1007\/s00105-024-05359-y","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,14]]},"assertion":[{"value":"19 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>P.\u00a0Nenoff<\/b>: A.\u00a0Finanzielle Interessen: Advisory Board Galderma, Dr. Pfleger.\u00a0\u2013 Pfizer, Sanofi SA.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Laborarzt in eigener Niederlassung | Mitgliedschaften: DDG, BVDD, DMykG, ADI-TD. <b>E.\u00a0Klonowski<\/b>: A.\u00a0Finanzielle Interessen: E.\u00a0Klonowski gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellte: Biologin bei labopart\u00a0\u2013 medizinische Laboratorien. <b>S.\u00a0Uhrla\u00df<\/b>: A.\u00a0Finanzielle Interessen: Almirall Honorar zum Myko-Kurs, Kostenerstattung f\u00fcr Hotel- und Reisekosten; Biomerieux Honorar zum Myko-Kurs, Kostenerstattung f\u00fcr Hotel- und Reisekosten.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Arbeitgeber: labopart, Medizinische Laboratorien, Standort Leipzig M\u00f6lbis, Prof. Nenoff | Gastwissenschaftler Hautklinik Leipzig, Prof. Simon, von 10\/2022 bis 12\/2023 (ohne Honorar) | Mitgliedschaft: DMykG. <b>M.\u00a0Schaller<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zu meiner pers\u00f6nlichen Verf\u00fcgung von Galderma.\u00a0\u2013 Honorar f\u00fcr Vortr\u00e4ge von Galderma.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Stellv. \u00c4rztlicher Direktor, Leitender Oberarzt, Universit\u00e4ts-Hautklinik T\u00fcbingen | Mitgliedschaft: Deutschsprachige mykologische Gesellschaft. <b>U.\u00a0Paasch<\/b>: A.\u00a0Finanzielle Interessen: U.\u00a0Paasch gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Niedergelassener Dermatologe, Jesewitz OT Gotha, Praxisinhaber; Angestellter OA, Dermatologie, Klinik f\u00fcr Dermatologie, Venerologie und Allergologie | Mitgliedschaften: DDG, DGA, DDL, ESLD, ASLMS, SLAEK, ADH | Pr\u00e4sident past DDL, Vize-Pr\u00e4sident past ESLD. <b>P.\u00a0Mayser<\/b>: A.\u00a0Finanzielle Interessen: Erstellung von Fortbildungsheften und dabei gelegentlich Beratungsfunktion f\u00fcr die Fa. Almirall-Hermal.\u00a0\u2013 Aktien Fa. Novartis, Fa. Bayer.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Im Ruhestand | Mitgliedschaften: DDG, DMykG.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}